Source: Wang, D. et al. In Vitro Tumor Cell Rechallenge for Predictive Evaluation of Chimeric Antigen Receptor T cell Antitumor Function. J. Vis. Exp. (2019)
In this video, we demonstrate the repetitive tumor challenge assay to evaluate the CAR T cells’ repetitive tumor killing potential during high tumor cell loads. Further, the CAR T cells can be analyzed using flow cytometry to determine the different subpopulations of CAR T cells in the sample.
1. Media Preparation
2. Preparation of GBM Tumor Cells
3. Preparation of CAR T Cells
4. Set up tumor — T Cell Co-culture
5. Tumor Cell Rechallenge
NOTE: Rechallenge takes place at 2, 4 and 6 days post the initial co-culture setup (Figure 1A).
6. Harvest Samples and Flow Cytometric Analysis
NOTE: Samples will be harvested at 1, 3, 5 and 7 days post the initial co-culture setup, with 1, 2, 3 and 4 rounds of tumor challenge, respectively.
Table 1: Representative plate map of rechallenge setup.
Figure 1: Schema and analysis strategy of repetitive challenge assay. (A) Schema and timeline of repetitive tumor challenge assay. For each well, CAR T cells were first co-cultured with PBT030-2 GBM cells (4,000 CAR+ cells, 16,000 tumor cells) and re-challenged with 32,000 tumor cells every other day (D2, D4 and D6). Analysis of tumor cell and CAR T cell number, as well as CAR T cell phenotype is carried out at D1, D3, D5 and D7. (B) Gating strategy to determine CAR% in T cells before setting up the co-culture. (C) Gating strategy of live cells, tumor cells and CAR T cells from the repetitive challenge assay. (D) Tumor cells number at different times of the rechallenge assay, co-cultured with untransduced T cells. Error bars = ±SEM.
The authors have nothing to disclose.
0.05% Trypsin/0.53mM EDTA in HBSS without Calcium and Magnesium | Corning | MT25051CI | |
1 M Hepes | Irvine Scientific | 9319 | |
200 mM L-Glutamine | Cambrex Bio Science | 17-605E | |
4',6-diamidino-2-phenylindole, dihydrochloride (DAPI) – FluoroPure grade | Invitrogen | D21490 | |
Accutase | Innovative Cell Technologies | AT104 | |
Aldesleukin Proleukin (rhIL-2) | Novartis Oncology | NDC 0078-0495-61 | |
Anti-CD137, PE | BD Biosciences | 555956 | 4B4-1 |
Anti-CD19, PE-Cy7 | BD Biosciences | 557835 | SJ25C1 |
Anti-CD3, PERCP | BD Biosciences | 340663 | SK7 |
Anti-CD4, FITC | BD Biosciences | 340133 | SK3 |
Anti-CD45, PERCP | BD Biosciences | 340665 | 2D1 |
Anti-CD45RO, PE | BD Biosciences | 561137 | UCHL1 |
Anti-CD62L, APC | BD Biosciences | 559772 | DREG-56 |
Anti-CD69, APC | BD Biosciences | 340560 | L78 |
Anti-CD8, APC-Cy7 | BD Biosciences | 348793 | SK1 |
Anti-IL-13, PE | BD Biosciences | 340508 | JES10-5A2 |
Anti-LAG-3, PE | eBiosciences | 12-2239-41 | 3DS223H |
Anti-PD-1, APC-Cy7 | BioLegend | 329921 | EH12.2H7 |
Anti-TIM-3, APC | eBiosciences | 17-3109-42 | F38-2E2 |
B-27 Serum-Free Supplement (50x) | Invitrogen | 17504-044 | |
Corning 96 Well Clear Flat Bottom Polystyrene TC-Treated Microplates, Individually Wrapped, with Lid, Sterile (Product #3596) | Corning Life Sciences | 3596 | |
Defined fetal bovine serum,HI IR | Hyclone Labs | SH30070.03IH | |
DMEM F-12 50:50 (1x) without Glutamine | MediaTech, Inc. | 15-090-CV | |
DMEM High Gluc w/o L-Glu, Na Pyr 1 L | Invitrogen | 11960051 | |
DMEM-Ham's F12 50:50 Mixture with L-glutamine and 15 mM HEPES | Fisher Scientific | MT10092CV | |
HBSS | Irvine Scientific | 9224 | |
Heat-Inactivated FCS | Hyclone | SH30070.03 | |
Heparin Sodium(1,000 U/mL) | American Pharmaceutical | 401811B | |
PBS 1x W/CA & MG | Irvine Scientific | 9236 | |
PBS with 1 mM EDTA (No Ca2+ or Mg2+) | VWR Scientific Products | PB15009A | |
rhIL-15 Working Dilution (10 ng/µL) | CellGenix, US Operations | tF0297 | |
Sodium Azide (NaN3) | Sigma | S8032 | |
Recombinant human EGF | R&D Systems | 236-EG-200 | |
Recombinant human FGF | R&D Systems | 233-FB |